Microarray analysis identifies a death-from-cancer signature predicting therapy failure in patients with multiple types of cancer
Open accessThe DOI matches its Crossref record; 69 of the 69 references it cites were found in a registry or an index.
Abstract
Activation in transformed cells of normal stem cells' self-renewal pathways might contribute to the survival life cycle of cancer stem cells and promote tumor progression. The BMI-1 oncogene-driven gene expression pathway is essential for the self-renewal of hematopoietic and neural stem cells. We applied a mouse/human comparative translational genomics approach to identify an 11-gene signature that consistently displays a stem cell-resembling expression profile in distant metastatic lesions as revealed by the analysis of metastases and primary tumors from a transgenic mouse model of prostate cancer and cancer patients. To further validate these results, we examined the prognostic power of the 11-gene signature in several independent therapy-outcome sets of clinical samples obtained from 1,153 cancer patients diagnosed with 11 different types of cancer, including 5 epithelial malignancies (prostate, breast, lung, ovarian, and bladder cancers) and 5 nonepithelial malignancies (lymphoma, mesothelioma, medulloblastoma, glioma, and acute myeloid leukemia). Kaplan-Meier analysis demonstrated that a stem cell-like expression profile of the 11-gene signature in primary tumors is a consistent powerful predictor of a short interval to disease recurrence, distant metastasis, and death after therapy in cancer patients diagnosed with 11 distinct types of cancer. These data suggest the presence of a conserved BMI-1-driven pathway, which is similarly engaged in both normal stem cells and a highly malignant subset of human cancers diagnosed in a wide range of organs and uniformly exhibiting a marked propensity toward metastatic dissemination as well as a high probability of unfavorable therapy outcome.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Elevated expression of this signature is associated with cancer development and chemotherapy resistance in different types of cancer, including hematological malignancies.11”
From USP22 deficiency leads to myeloid leukemia upon oncogenic Kras activation through a PU.1-dependent mechanism (2018) · cites this paper as [11]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Prospective identification of tumorigenic breast cancer cells
Al-Hajj, M., Wicha, M. S., Benito-Hernandez, A., Morrison, S. J., & Clarke, M. F. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0530291100 · Cited by 10,370
Gene expression profiling predicts clinical outcome of breast cancer
van 't Veer, L. J., Dai, H., van de Vijver, M. J., He, Y. D., Hart, A. A. M., Mao, M., Peterse, H. L., van der Kooy, K., Marton, M. J., Witteveen, A. T., et al. (2002) · Nature · doi:10.1038/415530a · Cited by 9,536 · cited 4×
“We therefore sought to investigate whether measurements of expression of the 11-gene MTTS/PNS signature would be informative in the prediction of the patients’ prognosis in a group of 97 young women diagnosed with sporadic lymph node– negative early-stage breast cancer who were analyzed in a recent expression profilin…”
BackgroundMethodInfluentialA Gene-Expression Signature as a Predictor of Survival in Breast Cancer
van de Vijver, M. J., He, Y. D., van 't Veer, L. J., Dai, H., Hart, A. A. M., Voskuil, D. W., Schreiber, G. J., Peterse, J. L., Roberts, C., Marton, M. J., et al. (2002) · New England Journal of Medicine · doi:10.1056/nejmoa021967 · Cited by 6,488
Rosenwald, A., Wright, G., Chan, W. C., Connors, J. M., Campo, E., Fisher, R. I., Gascoyne, R. D., Muller-Hermelink, H. K., Smeland, E. B., Giltnane, J. M., et al. (2002) · New England Journal of Medicine · doi:10.1056/nejmoa012914 · Cited by 3,829
The polycomb group protein EZH2 is involved in progression of prostate cancer
Varambally, S., Dhanasekaran, S. M., Zhou, M., Barrette, T. R., Kumar-Sinha, C., Sanda, M. G., Ghosh, D., Pienta, K. J., Sewalt, R. G. A. B., Otte, A. P., et al. (2002) · Nature · doi:10.1038/nature01075 · Cited by 2,717
Bhattacharjee, A., Richards, W. G., Staunton, J., Li, C., Monti, S., Vasa, P., Ladd, C., Beheshti, J., Bueno, R., Gillette, M., et al. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.191502998 · Cited by 2,576
Gene expression correlates of clinical prostate cancer behavior
Singh, D., Febbo, P. G., Ross, K., Jackson, D. G., Manola, J., Ladd, C., Tamayo, P., Renshaw, A. A., D'Amico, A. V., Richie, J. P., et al. (2002) · Cancer Cell · doi:10.1016/s1535-6108(02)00030-2 · Cited by 2,512
Systematic determination of genetic network architecture
Tavazoie, S., Hughes, J. D., Campbell, M. J., Cho, R. J., & Church, G. M. (1999) · Nature Genetics · doi:10.1038/10343 · Cited by 2,507 · cited 1×
“We calculated the significance of the overlap between the lists of stem cell–associated and prostate cancer–associated genes by using the hypergeometric distribution test (54).”
MethodA molecular signature of metastasis in primary solid tumors
Ramaswamy, S., Ross, K. N., Lander, E. S., & Golub, T. R. (2003) · Nature Genetics · doi:10.1038/ng1060 · Cited by 2,449
Shipp, M. A., Ross, K. N., Tamayo, P., Weng, A. P., Kutok, J. L., Aguiar, R. C. T., Gaasenbeek, M., Angelo, M., Reich, M., Pinkus, G. S., et al. (2002) · Nature Medicine · doi:10.1038/nm0102-68 · Cited by 2,428
Cited by
Ginestier, C., Hur, M. H., Charafe-Jauffret, E., Monville, F., Dutcher, J., Brown, M., Jacquemier, J., Viens, P., Kleer, C. G., Liu, S., et al. (2007) · Cell Stem Cell · doi:10.1016/j.stem.2007.08.014 · Cited by 4,012
Gene-Expression Signatures in Breast Cancer
Sotiriou, C., & Pusztai, L. (2009) · New England Journal of Medicine · doi:10.1056/nejmra0801289 · Cited by 1,485
Cancer stem cells: an old idea–a paradigm shift
Wicha, M. S., Liu, S., & Dontu, G. (2006) · Cancer Research · doi:10.1158/0008-5472.can-05-3153 · Cited by 1,378
“was associated with a poor prognosis for 10 different types of human malignancies (52).”
BackgroundMolecular Definition of Breast Tumor Heterogeneity
Shipitsin, M., Campbell, L. L., Argani, P., Weremowicz, S., Bloushtain-Qimron, N., Yao, J., Nikolskaya, T., Serebryiskaya, T., Beroukhim, R., Hu, M., et al. (2007) · Cancer Cell · doi:10.1016/j.ccr.2007.01.013 · Cited by 1,353
“…of an 11-gene, BMI1-driven stem cell gene signature in a large collection of gene expression data from several different tumor types determined that this signature is a powerful predictor of short diseasefree and overall survival and the risk of distant metastases (Glinsky et al., 2005).”
BackgroundPolycomb silencers control cell fate, development and cancer
Sparmann, A., & van Lohuizen, M. (2006) · Nature Reviews Cancer · doi:10.1038/nrc1991 · Cited by 1,303
Hedgehog Signaling and Bmi-1 Regulate Self-renewal of Normal and Malignant Human Mammary Stem Cells
Liu, S., Dontu, G., Mantle, I. D., Patel, S., Ahn, N.-S., Jackson, K. W., Suri, P., & Wicha, M. S. (2006) · Cancer Research · doi:10.1158/0008-5472.can-06-0054 · Cited by 1,244
“The clinical importance of this is highlighted by a recent report demonstrating a strong correlation between the expression of an 11-gene Bmi-1 stem cell signature and poor prognosis in patients with a wide variety of malignancies (36).”
BackgroundCharafe-Jauffret, E., Ginestier, C., Iovino, F., Wicinski, J., Cervera, N., Finetti, P., Hur, M.-H., Diebel, M. E., Monville, F., Dutcher, J., et al. (2009) · Cancer Research · doi:10.1158/0008-5472.can-08-2741 · Cited by 1,173
“A link between CSC and metastasis was first suggested with the identification of stem cell genes in an 11-gene signature generated using comparative profiles of metastatic and primary tumors in a transgenic mouse model of prostate cancer and in cancer patients (49).”
The Prognostic Role of a Gene Signature from Tumorigenic Breast-Cancer Cells
Liu, R., Wang, X., Chen, G. Y., Dalerba, P., Gurney, A., Hoey, T., Sherlock, G., Lewicki, J., Shedden, K., & Clarke, M. F. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa063994 · Cited by 985
de Azambuja, E., Cardoso, F., de Castro, G., Colozza, M., Mano, M. S., Durbecq, V, Sotiriou, C., Larsimont, D., Piccart-Gebhart, M. J., & Paesmans, M. (2007) · British Journal of Cancer · doi:10.1038/sj.bjc.6603756 · Cited by 959
Merlos-Suárez, A., Barriga, F. M., Jung, P., Iglesias, M., Céspedes, M. V., Rossell, D., Sevillano, M., Hernando-Momblona, X., da Silva-Diz, V., Muñoz, P., et al. (2011) · Cell Stem Cell · doi:10.1016/j.stem.2011.02.020 · Cited by 934
“This notion has spread from studies that used expression signatures derived from tumor-initiating cells (Glinsky et al., 2005).”
BackgroundRadial glia cells are candidate stem cells of ependymoma
Taylor, M. D., Poppleton, H., Fuller, C., Su, X., Liu, Y., Jensen, P., Magdaleno, S., Dalton, J., Calabrese, C., Board, J., et al. (2005) · Cancer Cell · doi:10.1016/j.ccr.2005.09.001 · Cited by 829
“One of the most immediate clinical applications of cancer stem cell biology is the generation of prognostic tools (Glinsky et al., 2005; Singh et al., 2003).”
BackgroundCuzick, J., Swanson, G. P., Fisher, G., Brothman, A. R., Berney, D. M., Reid, J. E., Mesher, D., Speights, V., Stankiewicz, E., Foster, C. S., et al. (2011) · The Lancet Oncology · doi:10.1016/s1470-2045(10)70295-3 · Cited by 792
Metastasis: recent discoveries and novel treatment strategies
Eccles, S. A., & Welch, D. R. (2007) · The Lancet · doi:10.1016/s0140-6736(07)60781-8 · Cited by 721
Seyfried, T. N., & Shelton, L. M. (2010) · Nutrition & Metabolism · doi:10.1186/1743-7075-7-7 · Cited by 644
“Fusions among metastatic myeloid cells at the primary tumor site could, through reprogramming strategies, also produce functional epithelial cells at secondary sites potentially simulating the histological characteristics of the original tissue of origin [200,211,212].”
BackgroundCommon markers of proliferation
Whitfield, M. L., George, L. K., Grant, G. D., & Perou, C. M. (2006) · Nature Reviews Cancer · doi:10.1038/nrc1802 · Cited by 650
“This pattern was associated with poor outcomes in patients with a variety of tumour type”
BackgroundErho, N., Crisan, A., Vergara, I. A., Mitra, A. P., Ghadessi, M., Buerki, C., Bergstralh, E. J., Kollmeyer, T., Fink, S., Haddad, Z., et al. (2013) · PLoS ONE · doi:10.1371/journal.pone.0066855 · Cited by 644
“The performance of GC was compared to that of previously published gene signatures [11–13,15,16,18–24,28–30] and individual genomic markers associated with prostate cancer progression including CHGA [43], DAB2IP [44], GOLPH2 [45], PAP [46], ETV1 and ERG [47], KI-67 [48], PSA [49], PSCA [50], PSMA [51], AMACR [52], GST…”
BackgroundResultYu, Z., Pestell, T. G., Lisanti, M. P., & Pestell, R. G. (2012) · The International Journal of Biochemistry & Cell Biology · doi:10.1016/j.biocel.2012.08.022 · Cited by 647
Inferring Pathway Activity toward Precise Disease Classification
Lee, E., Chuang, H.-Y., Kim, J.-W., Ideker, T., & Lee, D. (2008) · PLoS Computational Biology · doi:10.1371/journal.pcbi.1000217 · Cited by 600
“Alternative approaches engineer normal cells to activate pre-selected oncogenic pathways to determine gene signatures which can distinguish tumor characteristics [20,25].”
BackgroundMost Random Gene Expression Signatures Are Significantly Associated with Breast Cancer Outcome
Venet, D., Dumont, J. E., & Detours, V. (2011) · PLoS Computational Biology · doi:10.1371/journal.pcbi.1002240 · Cited by 586
“These include signatures of stem cells [13–15], aneuploidy [16], wound healing [17,18], hypoxia [19,20], stromal component [21], epithelialmesenchymal transition [22–24]; of mutations in TP53 [25], ALK5 [26]; of loss of PTEN [27]; of perturbations of E2F1 [28], bromodomain 4 [29], mir31 targets [30], p18 [31], retinoi…”
BackgroundCairo, S., Armengol, C., De Reyniès, A., Wei, Y., Thomas, E., Renard, C.-A., Goga, A., Balakrishnan, A., Semeraro, M., Gresh, L., et al. (2008) · Cancer Cell · doi:10.1016/j.ccr.2008.11.002 · Cited by 509
“A salient feature of immature HBs is the characteristic interplay of stemness and high proliferation found in aggressive tumors (Glinsky et al., 2005).”
BackgroundTargeting Mitosis in Cancer: Emerging Strategies
Dominguez-Brauer, C., Thu, K. L., Mason, J. M., Blaser, H., Bray, M. R., & Mak, T. W. (2015) · Molecular Cell · doi:10.1016/j.molcel.2015.11.006 · Cited by 495
“High expression of Bub1 occurs in a variety of human tumor types (Grabsch et al., 2003; van ’t Veer et al., 2002) and often correlates with poor clinical prognosis (Glinsky et al., 2005; Sotiriou et al., 2003).”
BackgroundWeigelt, B., Baehner, F. L., & Reis‐Filho, J. S. (2010) · The Journal of Pathology · doi:10.1002/path.2648 · Cited by 482
“Glinsky et al [112] reasoned that the ability of transformed cells to self-renew might contribute to tumour progression and focused their study on BMI1, which regulates self-renewal of haematopoietic and neural stem cells.”
BackgroundSotiriou, C., & Piccart, M. J. (2007) · Nature Reviews Cancer · doi:10.1038/nrc2173 · Cited by 461
“Based on the concept that cancer stem cells in primary tumours may be the driving force for tumour progression and metastasis, Glinsky and colleague”
BackgroundLi, W., Ma, H., Zhang, J., Zhu, L., Wang, C., & Yang, Y. (2017) · Scientific Reports · doi:10.1038/s41598-017-14364-2 · Cited by 454
Geiger, T. R., & Peeper, D. S. (2009) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2009.07.006 · Cited by 431
Kalverda, B., Pickersgill, H., Shloma, V. V., & Fornerod, M. (2010) · Cell · doi:10.1016/j.cell.2010.01.011 · Cited by 442
“, 2007), and the human homologs of several of the group (Cyclin B, Bub1, Plk4, and Mad2) are included in ‘‘death-from-cancer’’ gene signatures (Glinsky et al., 2005; Glinsky, 2006): high expression of this signature set of genes correlates with an unfavorable outcome in several types of cancer.”
Zhang, X.-Y., Varthi, M., Sykes, S. M., Phillips, C., Warzecha, C., Zhu, W., Wyce, A., Thorne, A. W., Berger, S. L., & McMahon, S. B. (2008) · Molecular Cell · doi:10.1016/j.molcel.2007.12.015 · Cited by 427
“USP22 is one of a small set of marker genes capable of predicting metastatic potential and therapeutic outcome in human cancer (Glinsky, 2005, 2006; Glinsky et al., 2005).”
BackgroundInfluentialSong, L.-B., Li, J., Liao, W.-T., Feng, Y., Yu, C.-P., Hu, L.-J., Kong, Q.-L., Xu, L.-H., Zhang, X., Liu, W.-L., et al. (2009) · Journal of Clinical Investigation · doi:10.1172/jci39374 · Cited by 398
“Dysregulation of Bmi-1 alters cell proliferation, apoptosis, senescence, and stem cell self-renewal and correlates with the invasive and metastatic phenotype of several human cancer types (14, 16, 18, 20, 49, 50).”
BackgroundRoots and stems: stem cells in cancer
Polyak, K., & Hahn, W. C. (2006) · Nature Medicine · doi:10.1038/nm1379 · Cited by 378
Tumor Cell-Organ Microenvironment Interactions in the Pathogenesis of Cancer Metastasis
Langley, R. R., & Fidler, I. J. (2007) · Endocrine Reviews · doi:10.1210/er.2006-0027 · Cited by 373
Motoi, N., Szoke, J., Riely, G. J., Seshan, V. E., Kris, M. G., Rusch, V. W., Gerald, W. L., & Travis, W. D. (2008) · American Journal of Surgical Pathology · doi:10.1097/pas.0b013e31815cb162 · Cited by 371
Siddique, H. R., & Saleem, M. (2012) · STEM CELLS · doi:10.1002/stem.1035 · Cited by 339
Song, L.-B., Zeng, M.-S., Liao, W.-T., Zhang, L., Mo, H.-Y., Liu, W.-L., Shao, J.-Y., Wu, Q.-L., Li, M.-Z., Xia, Y.-F., et al. (2006) · Cancer Research · doi:10.1158/0008-5472.can-06-0094 · Cited by 329
“In agreement with the published report (19), BUB1, HEC1 , and KI67 were found to be consistently up-regulated, whereas CES and ANK3 were consistently down-regulated in Bmi-1-immortalized cells (Fig.”
BackgroundResultChuang, H.-Y., Hofree, M., & Ideker, T. (2010) · Annual Review of Cell and Developmental Biology · doi:10.1146/annurev-cellbio-100109-104122 · Cited by 319
“Others have engineered normal cells to activate preselected oncogenic pathways to determine gene signatures that can distinguish tumor characteristics (Bild et al. 2006, Glinsky et al. 2005).”
Histone Ubiquitination and Deubiquitination in Transcription, DNA Damage Response, and Cancer
Cao, J., & Yan, Q. (2012) · Frontiers in Oncology · doi:10.3389/fonc.2012.00026 · Cited by 313
“High level of USP22 in tumor tissues is associated with poor clinical outcome, including high risk of recurrence, metastasis, and resistance to chemotherapy (Glinsky, 2005; Glinsky et al., 2005; Zhang et al., 2011).”
BackgroundMolecular interactions in cancer cell metastasis
Brooks, S. A., Lomax-Browne, H. J., Carter, T. M., Kinch, C. E., & Hall, D. M. S. (2010) · Acta Histochemica · doi:10.1016/j.acthis.2008.11.022 · Cited by 312
Mir-30 reduction maintains self-renewal and inhibits apoptosis in breast tumor-initiating cells
Yu, F., Deng, H., Yao, H., Liu, Q., Su, F., & Song, E. (2010) · Oncogene · doi:10.1038/onc.2010.167 · Cited by 301
Fasano, C. A., Dimos, J. T., Ivanova, N. B., Lowry, N., Lemischka, I. R., & Temple, S. (2007) · Cell Stem Cell · doi:10.1016/j.stem.2007.04.001 · Cited by 301
“Bmi-1 can be upregulated in brain tumors, such as medulloblastoma and glioblastoma, which have been linked to a stem cell-like origin (Hemmati et al., 2003; Leung et al., 2004; Glinsky et al., 2005 ).”
BackgroundRetractedA Translational View of the Molecular Pathogenesis of Lung Cancer
Sato, M., Shames, D. S., Gazdar, A. F., & Minna, J. D. (2007) · Journal of Thoracic Oncology · doi:10.1097/01.jto.0000263718.69320.4c · Cited by 297
Mechanisms that link the oncogenic epithelial–mesenchymal transition to suppression of anoikis
Frisch, S. M., Schaller, M., & Cieply, B. (2013) · Journal of Cell Science · doi:10.1242/jcs.120907 · Cited by 295
“In addition, ankyrin-G is downregulated in diverse types of tumor, and is included in a signature – consisting of eleven genes – that correlates with poor prognosis following chemotherapy of cancer patients (Glinsky et al., 2005).”
BackgroundSignificance, detection and markers of disseminated breast cancer cells
Lacroix, M. (2006) · Endocrine-Related Cancer · doi:10.1677/erc-06-0001 · Cited by 293
Isolation and Molecular Characterization of Cancer Stem Cells in MMTV-Wnt-1 Murine Breast Tumors
Cho, R. W., Wang, X., Diehn, M., Shedden, K., Chen, G. Y., Sherlock, G., Gurney, A., Lewicki, J., & Clarke, M. F. (2008) · Stem Cells · doi:10.1634/stemcells.2007-0440 · Cited by 292
The Unique Molecular and Cellular Microenvironment of Ovarian Cancer
Worzfeld, T., Pogge von Strandmann, E., Huber, M., Adhikary, T., Wagner, U., Reinartz, S., & Müller, R. (2017) · Frontiers in Oncology · doi:10.3389/fonc.2017.00024 · Cited by 288
“Finally, a microarray study published in 2005 (30) identified an 11-gene signature characteristic of relapsed HGSOC, but mechanistic links to therapy resistance remain hypothetical.”
BackgroundShema, E., Tirosh, I., Aylon, Y., Huang, J., Ye, C., Moskovits, N., Raver-Shapira, N., Minsky, N., Pirngruber, J., Tarcic, G., et al. (2008) · Genes & Development · doi:10.1101/gad.1703008 · Cited by 287
“Furthermore, USP22 is required for cell cycle progression (Glinsky et al. 2005; Widschwendter et al. 2007; Zhang et al. 2008).”
Bacac, M., & Stamenkovic, I. (2008) · Annual Review of Pathology: Mechanisms of Disease · doi:10.1146/annurev.pathmechdis.3.121806.151523 · Cited by 286
Cancer Stem Cells: A Step Toward the Cure
Boman, B. M., & Wicha, M. S. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2008.17.7436 · Cited by 278
Bmi-1 Is a Crucial Regulator of Prostate Stem Cell Self-Renewal and Malignant Transformation
Lukacs, R. U., Memarzadeh, S., Wu, H., & Witte, O. N. (2010) · Cell Stem Cell · doi:10.1016/j.stem.2010.11.013 · Cited by 268
“Microarray meta-analyses have found that the presence of Bmi-1 in prostate cancer specimens often indicates metastatic disease and a high probability of unfavorable therapeutic outcome (Glinsky et al., 2005).”
BackgroundMultiple faces of the SAGA complex
Koutelou, E., Hirsch, C. L., & Dent, S. Y. (2010) · Current Opinion in Cell Biology · doi:10.1016/j.ceb.2010.03.005 · Cited by 261
“The deubiquitination activity of the hSAGA complex has also been implicated in cancer, as USP22 has been grouped by transcriptional profiling into an 11-gene ‘signature’ of poor prognosis in multiple types of cancer [59 ,74].”
MethodHussain, S., Zhang, Y., & Galardy, P. (2009) · Cell Cycle · doi:10.4161/cc.8.11.8739 · Cited by 260
Bone metastases from differentiated thyroid carcinoma
Muresan, M. M., Olivier, P., Leclere, J., Sirveaux, F., Brunaud, L., Klein, M., Zarnegar, R., & Weryha, G. (2008) · Endocrine Related Cancer · doi:10.1677/erc-07-0229 · Cited by 260
Gatza, M. L., Silva, G. O., Parker, J. S., Fan, C., & Perou, C. M. (2014) · Nature Genetics · doi:10.1038/ng.3073 · Cited by 258
Molecular Biology of Lung Cancer
Nana-Sinkam, S. P., & Powell, C. A. (2013) · Chest · doi:10.1378/chest.12-2346 · Cited by 248
Identifying Cancer Stem Cells in Solid Tumors: Case Not Proven
Hill, R. P. (2006) · Cancer Research · doi:10.1158/0008-5472.can-05-3450 · Cited by 248
Tomida, S., Takeuchi, T., Shimada, Y., Arima, C., Matsuo, K., Mitsudomi, T., Yatabe, Y., & Takahashi, T. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.19.7053 · Cited by 242
MiR-15a and MiR-16 Control Bmi-1 Expression in Ovarian Cancer
Bhattacharya, R., Nicoloso, M., Arvizo, R., Wang, E., Cortez, A., Rossi, S., Calin, G. A., & Mukherjee, P. (2009) · Cancer Research · doi:10.1158/0008-5472.can-09-2552 · Cited by 240
“Recent experimental observations documented increased expression of Bmi-1 in human non–small-cell lung cancer (7), breast carcinoma (8), prostate carcinoma (9), and in 80.”
BackgroundGuo, B.-H., Feng, Y., Zhang, R., Xu, L.-H., Li, M.-Z., Kung, H.-F., Song, L.-B., & Zeng, M.-S. (2011) · Molecular Cancer · doi:10.1186/1476-4598-10-10 · Cited by 228
“Although increasing evidence has shown that Bmi-1 expression is associated with unfavorable prognosis [16,17], other studies have not confirmed these findings [18,19].”
ResultDong, P., Kaneuchi, M., Watari, H., Hamada, J., Sudo, S., Ju, J., & Sakuragi, N. (2011) · Molecular Cancer · doi:10.1186/1476-4598-10-99 · Cited by 220
“BMI-1 (B lymphoma mouse Moloney leukemia virus insertion region 1) is a self-renewal gene and overexpressed in multiple human cancers, including lung cancer [4], breast cancer [5], prostate cancer [6], ovarian cancer [7], and recently EC [8].”
BackgroundMolecular sampling of prostate cancer: a dilemma for predicting disease progression
Sboner, A., Demichelis, F., Calza, S., Pawitan, Y., Setlur, S. R., Hoshida, Y., Perner, S., Adami, H.-O., Fall, K., Mucci, L. A., et al. (2010) · BMC Medical Genomics · doi:10.1186/1755-8794-3-8 · Cited by 218
“) and the current study, it is therefore impressive that all of these reports using different platforms and patient populations achieve similar results [43-49].”
Ling, S., Shan, Q., Zhan, Q., Ye, Q., Liu, P., Xu, S., He, X., Ma, J., Xiang, J., Jiang, G., et al. (2020) · Gut · doi:10.1136/gutjnl-2019-319616 · Cited by 216
Tu, Y., Gao, X., Li, G., Fu, H., Cui, D., Liu, H., Jin, W., & Zhang, Y. (2013) · Cancer Research · doi:10.1158/0008-5472.can-13-0358 · Cited by 209
“Bmi1 is a polycomb group epigenetic gene silencer that is highly expressed in various types of human cancers (27).”
BackgroundCancer Stem Cells: An Old Idea--A Paradigm Shift
Wicha, M. S., Liu, S., & Dontu, G. (2008) · AACR Education book · doi:10.1158/aacr.edb-can-05-3153 · Cited by 207
Coordinated Regulation of Polycomb Group Complexes through microRNAs in Cancer
Cao, Q., Mani, R.-S., Ateeq, B., Dhanasekaran, S. M., Asangani, I. A., Prensner, J. R., Kim, J. H., Brenner, J. C., Jing, X., Cao, X., et al. (2011) · Cancer Cell · doi:10.1016/j.ccr.2011.06.016 · Cited by 204
“Like PRC2 component EZH2, BMI1 and RING2 have been shown to be elevated in a number of tumor types (Glinsky et al., 2005; Sánchez-Beato et al., 2006) and regulate self-renewal of embryonic stem cells and cancer stem cells (Galmozzi et al.”
New molecularly targeted therapies for lung cancer
Sun, S., Schiller, J. H., Spinola, M., & Minna, J. D. (2007) · Journal of Clinical Investigation · doi:10.1172/jci31809 · Cited by 201
Cancer Stem Cell Metabolism and Potential Therapeutic Targets
Snyder, V., Reed-Newman, T. C., Arnold, L., Thomas, S. M., & Anant, S. (2018) · Frontiers in Oncology · doi:10.3389/fonc.2018.00203 · Cited by 201
“A strong association between tumors with high CSC fractions and recurrence, poorer overall survival, and higher incidence of metastasis, underscores the significant prognostic and therapeutic implications of CSCs (104, 105).”
BackgroundNassar, Z. D., Mah, C. Y., Dehairs, J., Burvenich, I. J., Irani, S., Centenera, M. M., Helm, M., Shrestha, R. K., Moldovan, M., Don, A. S., et al. (2020) · eLife · doi:10.7554/elife.54166 · Cited by 197
Emerging roles of deubiquitinases in cancer‐associated pathways
Sacco, J. J., Coulson, J. M., Clague, M. J., & Urbé, S. (2010) · IUBMB Life · doi:10.1002/iub.300 · Cited by 196
Fan, C., Prat, A., Parker, J. S., Liu, Y., Carey, L. A., Troester, M. A., & Perou, C. M. (2011) · BMC Medical Genomics · doi:10.1186/1755-8794-4-3 · Cited by 192
A basal stem cell signature identifies aggressive prostate cancer phenotypes
Smith, B. A., Sokolov, A., Uzunangelov, V., Baertsch, R., Newton, Y., Graim, K., Mathis, C., Cheng, D., Stuart, J. M., & Witte, O. N. (2015) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1518007112 · Cited by 193
Cancer Stem Cells in Head and Neck Squamous Cell Cancer
Prince, M. E. P., & Ailles, L. E. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.15.1613 · Cited by 192
Targeting self-renewal pathways in cancer stem cells: clinical implications for cancer therapy
Borah, A., Raveendran, S., Rochani, A., Maekawa, T., & Kumar, D. S. (2015) · Oncogenesis · doi:10.1038/oncsis.2015.35 · Cited by 192
Bub1 overexpression induces aneuploidy and tumor formation through Aurora B kinase hyperactivation
Ricke, R. M., Jeganathan, K. B., & van Deursen, J. M. (2011) · Journal of Cell Biology · doi:10.1083/jcb.201012035 · Cited by 190
“Furthermore, independent studies of diverse tumor types have identified Bub1 as a gene whose up-regulation correlates with poor clinical prognosis (Sotiriou et al., 2003; Glinsky et al., 2005; Nakagawa et al., 2008).”
BackgroundCD44 Expression Predicts Local Recurrence after Radiotherapy in Larynx Cancer
de Jong, M. C., Pramana, J., van der Wal, J. E., Lacko, M., Peutz-Kootstra, C. J., de Jong, J. M., Takes, R. P., Kaanders, J. H., van der Laan, B. F., Wachters, J., et al. (2010) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-10-0799 · Cited by 185
A compact VEGF signature associated with distant metastases and poor outcomes
Hu, Z., Fan, C., Livasy, C., He, X., Oh, D. S., Ewend, M. G., Carey, L. A., Subramanian, S., West, R., Ikpatt, F., et al. (2009) · BMC Medicine · doi:10.1186/1741-7015-7-9 · Cited by 183
“Next, we tested for associations between a tumor's intrinsic subtype, the VEGF profile and other published expression profiles implicated in metastasis biology that included a) the 70-gene outcome predictor developed by van't Veer et al [10,11], b) the 'wound-response' profile [32], c) the hypoxia-induced cell line si…”
Target for cancer therapy: proliferating cells or stem cells
Blagosklonny, M. V. (2006) · Leukemia · doi:10.1038/sj.leu.2404075 · Cited by 184
Nakagawa, T., Kollmeyer, T. M., Morlan, B. W., Anderson, S. K., Bergstralh, E. J., Davis, B. J., Asmann, Y. W., Klee, G. G., Ballman, K. V., & Jenkins, R. B. (2008) · PLoS ONE · doi:10.1371/journal.pone.0002318 · Cited by 179
“The lowest Cramér’s V-statistic was between the true state (perfect prediction) and the Glinsky et al. 2005 model with clinical data.”
ResultMartínez-Alonso, D., & Malumbres, M. (2020) · Seminars in Cell & Developmental Biology · doi:10.1016/j.semcdb.2020.03.009 · Cited by 179
MYC regulation of a “poor-prognosis” metastatic cancer cell state
Wolfer, A., Wittner, B. S., Irimia, D., Flavin, R. J., Lupien, M., Gunawardane, R. N., Meyer, C. A., Lightcap, E. S., Tamayo, P., Mesirov, J. P., et al. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0914203107 · Cited by 177
Breast cancer chemoresistance: Emerging importance of cancer stem cells
Chuthapisith, S., Eremin, J., El-Sheemey, M., & Eremin, O. (2010) · Surgical Oncology · doi:10.1016/j.suronc.2009.01.004 · Cited by 174
“CSCs are postulated to be involved not only in carcinogenesis but also in tumour invasion and formation of metastases [10,11].”
BackgroundPlanche, A., Bacac, M., Provero, P., Fusco, C., Delorenzi, M., Stehle, J.-C., & Stamenkovic, I. (2011) · PLoS ONE · doi:10.1371/journal.pone.0018640 · Cited by 171
“A selection of genes associated with poor and good prognosis for breast ([23], Table 5) and prostate ([24], Table 5) cancer are shown.”
BackgroundHistone Modifiers in Cancer: Friends or Foes?
Cohen, I., Poreba, E., Kamieniarz, K., & Schneider, R. (2011) · Genes & Cancer · doi:10.1177/1947601911417176 · Cited by 171
Goel, H. L., Pursell, B., Chang, C., Shaw, L. M., Mao, J., Simin, K., Kumar, P., Kooi, C. W. V., Shultz, L. D., Greiner, D. L., et al. (2013) · EMBO Molecular Medicine · doi:10.1002/emmm.201202078 · Cited by 167
“A critical feature of GLI1 in this context is its ability to induce BMI-1, a transcriptional repressor that has been implicated in the function of mammary tumour stem cells (Glinsky et al, 2005; Liu et al, 2006).”
The central role of EED in the orchestration of polycomb group complexes
Cao, Q., Wang, X., Zhao, M., Yang, R., Malik, R., Qiao, Y., Poliakov, A., Yocum, A. K., Li, Y., Chen, W., et al. (2014) · Nature Communications · doi:10.1038/ncomms4127 · Cited by 164
Su, W., Xu, M., Chen, X., Chen, N., Gong, J., Nie, L., Li, L., Li, X., Zhang, M., & Zhou, Q. (2017) · Molecular Cancer · doi:10.1186/s12943-017-0711-y · Cited by 164
“BMI1 is over-expressed in prostate cancer with adverse pathologic and clinical features and the presence of BMI1 in prostate cancer specimens often indicates metastatic disease and a high probability of unfavorable therapeutic outcome [11, 12].”
Xie, Y., Xiao, G., Coombes, K. R., Behrens, C., Solis, L. M., Raso, G., Girard, L., Erickson, H. S., Roth, J., Heymach, J. V., et al. (2011) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-11-0196 · Cited by 162
“In addition, in mouse models, a hematopoietic and neural stem cell–like signature in primary tumors has been shown to be a predictor of poor prognosis in 11 types of cancer, including lung (43).”
BackgroundThe Lethal Phenotype of Cancer: The Molecular Basis of Death Due to Malignancy
Loberg, R. D., Bradley, D. A., Tomlins, S. A., Chinnaiyan, A. M., & Pienta, K. J. (2007) · CA: A Cancer Journal for Clinicians · doi:10.3322/canjclin.57.4.225 · Cited by 161
Prenzel, T., Begus-Nahrmann, Y., Kramer, F., Hennion, M., Hsu, C., Gorsler, T., Hintermair, C., Eick, D., Kremmer, E., Simons, M., et al. (2011) · Cancer Research · doi:10.1158/0008-5472.can-11-1896 · Cited by 160
The UHRF family: Oncogenes that are drugable targets for cancer therapy in the near future?
Bronner, C., Achour, M., Arima, Y., Chataigneau, T., Saya, H., & Schini-Kerth, V. B. (2007) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2007.06.003 · Cited by 159
Epigenetic regulation of normal and malignant hematopoiesis
Rice, K. L., Hormaeche, I., & Licht, J. D. (2007) · Oncogene · doi:10.1038/sj.onc.1210755 · Cited by 158
“Similarly, dysregulation of BMI1 also affects the activity of the PRCs, and overexpression and overactivity of BMI1 has been associated with a variety of solid tumors including lung, breast, colon, prostate and neuroblastoma as well as in malignant hematopoiesis (Breuer et al., 2004; Glinsky et al., 2005; Steele et al…”
BackgroundBerezovska, O. P., Glinskii, A. B., Yang, Z., Li, X., Hoffman, R. M., & Glinsky, G. V. (2006) · Cell Cycle · doi:10.4161/cc.5.16.3222 · Cited by 171
Self-citationCyclin B2 and p53 control proper timing of centrosome separation
Nam, H.-J., & van Deursen, J. M. (2014) · Nature Cell Biology · doi:10.1038/ncb2952 · Cited by 153
Prognostic DNA Methylation Biomarkers in Ovarian Cancer
Wei, S. H., Balch, C., Paik, H. H., Kim, Y.-S., Baldwin, R. L., Liyanarachchi, S., Li, L., Wang, Z., Wan, J. C., Davuluri, R. V., et al. (2006) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-05-1551 · Cited by 154
Differential Matrix Rigidity Response in Breast Cancer Cell Lines Correlates with the Tissue Tropism
Kostic, A., Lynch, C. D., & Sheetz, M. P. (2009) · PLoS ONE · doi:10.1371/journal.pone.0006361 · Cited by 153
Mimeault, M., & Batra, S. K. (2005) · Carcinogenesis · doi:10.1093/carcin/bgi229 · Cited by 169
Glinsky, G. V. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2008.17.0266 · Cited by 169
Self-citationHeterogeneity in Circulating Tumor Cells: The Relevance of the Stem-Cell Subset
Agnoletto, C., Corrà, F., Minotti, L., Baldassari, F., Crudele, F., Cook, W. J. J., Leva, G. D., D’Adamo, P., Gasparini, P., & Volinia, S. (2019) · Cancers · doi:10.3390/cancers11040483 · Cited by 152
BMI1 is a target gene of E2F-1 and is strongly expressed in primary neuroblastomas
Nowak, K. (2006) · Nucleic Acids Research · doi:10.1093/nar/gkl119 · Cited by 145
“Indeed, based on a list of genes differentially expressed in a mouse model of metastatic prostate cancer on a wild-type and bmi1 -deficient genetic background a gene signature was recently identified that may predict response to therapy and survival in multiple types of cancer (17).”
Dekel, B., Metsuyanim, S., Schmidt-Ott, K. M., Fridman, E., Jacob–Hirsch, J., Simon, A. J., Pinthus, J. H., Mor, Y., Barasch, J. M., Amariglio, N., et al. (2006) · Cancer Research · doi:10.1158/0008-5472.can-05-4528 · Cited by 151
“Recently, the BMI-1 oncogene–driven gene expression pathway has been shown to be essential for the self-renewal of cells from multiple types of human cancer (40).”
BackgroundMuinao, T., Boruah, H. P. D., & Pal, M. (2017) · Experimental Cell Research · doi:10.1016/j.yexcr.2017.10.018 · Cited by 163
Kolenda, J., Jensen, S. S., Aaberg-Jessen, C., Christensen, K., Andersen, C., Brünner, N., & Kristensen, B. W. (2011) · Journal of Neuro-Oncology · doi:10.1007/s11060-010-0357-8 · Cited by 144
“Regarding Bmi-1, belonging to the polycomb gene group [50], a complementary DNA (cDNA) microarray analysis has identified Bmi-1 and its associated genes as critical prognostic indicators of various cancers including gliomas [51].”
BackgroundGuo, W., Datta, S., Band, V., & Dimri, G. P. (2006) · Molecular Biology of the Cell · doi:10.1091/mbc.e06-05-0447 · Cited by 153
“Similar to our results, a very recent report has also implicated c-Myc in regulation of Bmi-1 expression and induction of telomere-independent senescence by reduced c-Myc levels and consequent increase in p16 (Guney et al., 2006).”
Result
Metadata
- Authors
- Glinsky, G. V., Berezovska, O., & Glinskii, A. B.
- Affiliations
- Sidney Kimmel Cancer Center (US)
- Corresponding author
- Glinsky, Gennadi V.
- ORCID
- Glinsky, Gennadi V.
- Venue
- Journal of Clinical Investigation
- Published
- 2005-06-01
- Volume
- 115
- Issue
- 6
- Pages
- 1503-1521
- ISSN
- 0021-9738 (ISSN-L)
- PMC
- PMC1136989
- OpenAlex
- W2166666333
- Cited by
- 916
- References
- 68
- Citations by year
- 2026: 6 · 2025: 10 · 2024: 22 · 2023: 30 · 2022: 25 · 2021: 29 · 2020: 25 · 2019: 27 · 2018: 38 · 2017: 35 · 2016: 30 · 2015: 50 · 2014: 57 · 2013: 51 · 2012: 60
- FWCI
- 34.21
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Journal of Clinical Investigation (publishedVersion)
- Europe PMC (PubMed Central) (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Memorial Sloan-Kettering Cancer Center
- National Institutes of Health
- National Cancer Institute (5R01CA89827, R01CA089827)
- Topics
- Health Sciences › Medicine › Oncology › Cancer Cells and Metastasis
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Prostate Cancer Treatment and Research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Gene expression and cancer classification
- Keywords
- cancer stem cells, BMI1, stem cell self-renewal, gene expression signatures, metastasis, treatment failure, prognosis, distant metastasis, recurrence, epithelial malignancies, hematologic malignancies, multi-cancer analysis
- MeSH terms
- Animals, Female, Humans, Male, Mice, Transgenic, Neoplasm Metastasis, Neoplasm Recurrence, Local, Neoplasms, Nuclear Proteins, Prognosis, Proto-Oncogene Proteins, Repressor Proteins, Biomarkers, Tumor, Neoplastic Stem Cells, Gene Expression Regulation, Neoplastic, Oligonucleotide Array Sequence Analysis, Gene Expression Profiling, Mice, Polycomb Repressive Complex 1
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.